Pittsburgh

Pittsburgh, PA – According to filings with the U.S. Securities and Exchange Commission, LyGenesis is raising $20,546,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Michael Hufford played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About LyGenesis

LyGenesis, Inc. is a cell therapy company focused on organ regeneration, transforming a patient’s lymph nodes into bioreactors capable of growing functioning ectopic organs. Our lead clinical indication is for patients with end stage liver disease (ESLD) and our Phase 2a clinical trial will begin in 2021. Other cell therapies in our drug development pipeline focus on regenerating pancreas, kidney, and thymus tissues. Instead of one donor organ treating one patient, LyGenesis’ technology enables one donor organ to treat dozens of patients. Instead of major surgery, LyGenesis uses outpatient endoscopic ultrasound for transplantation of its cell therapy, which enables cells to engraft, proliferate, and become a functioning ectopic organ.

To learn more about LyGenesis, visit http://www.lygenesis.com/

Contact:
Michael Hufford, Chief Executive Officer
412-449-9983
mhufford@lygenesis.com
https://www.linkedin.com/in/michael-hufford-4339596/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved